Tigecycline: In-vitro performance as a predictor of clinical efficacy

Clinical Microbiology and Infection

Volumn 13, Issue 4, 2007, Pages 354-362

  Hawkey, Peter ^a   Finch, R ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Glycylcyclines; Gram negative bacteria; In vitro performance; Multi drug resistance; Review; Tigecycline

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; EXPERIMENTAL MODEL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS;

ACINETOBACTER; ANIMALIA; BACILLI (CLASS); ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS;

EID: 33847792158     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01621.x     Document Type: Review

References (56)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41: 848-854.
2. Arpin C, Dubois V, Coulange L et.al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506-3514.
3. Livermore DM, Hawkey PM. CTX-M: Changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-454.
4. Diekema DJ, BootsMiller BJ, Vaughan TE et.al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004; 38: 78-85.
5. Livermore DM. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis 2003; 36 (suppl 1): S11-S23.
6. Jones RN. Resistance patterns among nosocomial pathogens: Trends over the past few years. Chest 2001; 119 (suppl 2): 397S-404S.
7. Henwood CJ, Gatward T, Warner M et.al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-487.
8. van Ogtrop ML, Andes D, Stamstad TJ et.al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 943-949.
9. Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38: 177-179.
10. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001; 40: 173-177.
11. Petersen PJ, Jacobus NV, Weiss WJ et.al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-744.
12. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49: 201-209.
13. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
14. Bush K. New beta-lactamases in gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-1089.
15. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-686.
16. Goussard S, Courvalin P. Updated sequence information for TEM beta-lactamase genes. Antimicrob Agents Chemother 1999; 43: 367-370.
17. Heritage J, M'Zali FH, Gascoyne-Binzi D, Hawkey PM. Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria. J Antimicrob Chemother 1999; 44: 309-318.
18. Mugnier P, Dubrous P, Casin I et.al. A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 2488-2493.
19. Bonnet R. Growing group of extended-spectrum beta-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
20. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002; 46: 1-11.
21. Shah AA, Hasan F, Ahmed S, Hameed A. Extended-spectrum beta-lactamases (ESBLs): Characterization, epidemiology and detection. Crit Rev Microbiol 2004; 30: 25-32.
22. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45: 583-588.
23. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: The quiet before the storm? Clin Microbiol Rev 2005; 18: 306-325.
24. Livermore DM, Woodford N. Carbapenemases: A problem in waiting? Curr Opin Microbiol 2000; 3: 489-495.
25. Lee K, Lee WG, Uh Y et.al. VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003; 9: 868-871.
26. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-260.
27. Bergeron J, Ammirati M, Danley D et.al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40: 2226-2228.
28. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-599.
29. Olson M, Ruzin A, Feyfant E, Rush TSO, Connell J, Bradford PA. Functional, biophysical and structural bases for antimicrobial activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2156-2166.
30. Bouchillon S, Stevens T, Johnson B et.al. Tigecycline Evaluation Surveillance Trial (TEST)-global in vitro antibacterial activity against Gran-positive and Gram-negative pathogens. Clin Microbiol Infect 2005; 11 (suppl 2): 241.
31. Bouchillon S, Stevens T, Johnson B et.al. Tigecycline Evaluation Surveillance Trial (TEST)-global in vitro antibacterial activity against selected species of glucose non-fermenting organisms. Clin Microbiol Infect 2005; 11 (suppl 2): 242.
32. Van Looveren M, Goosens H, ARPAC Steering Group. Antibacterial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
33. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-208.
34. Humphreys H, Towner KJ. Impact of Acinetobacter spp. in intensive care units in Great Britain and Ireland. J Hosp Infect 1997; 37: 281-286.
35. van der Broek PJ, Arends J, Bernards AT et.al. Epidemiology of multiple Acinetobacter outbreaks in The Netherlands. Clin Microbiol Infect 2006; 12: 837-843.
36. Oliva ME, Rekha A, Yellin A et.al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5: 88.
37. Poole K. Efflux-mediated antimicrobial resistance in Gram-negative bacteria. Clin Microbiol Infect 2004; 10: 12-26.
38. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005; 56: 20-51.
39. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-669.
40. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49: 791-793.
41. Dean CR, Visalli MA, Projan SJ et.al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-978.
42. Hirata T, Saito A, Nishino K et.al. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004; 48: 2179-2184.
43. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005; 49: 1017-1022.
44. Reynolds R, Potz N, Colman M et.al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: The BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53: 1018-1032.
45. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et.al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-4481.
46. Pitout JD, Laupland KB, Church DL et.al. Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005; 49: 4667-4670.
47. Rodriguez-Bano J, Navarro MD, Romero L et.al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: Implications for control. Clin Infect Dis 2006; 42: 37-45.
48. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.
49. Neuhauser MM, Weinstein RA, Rydman R et.al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003; 289: 885-888.
50. Jones RN, Pfaller MA, Doern GV et.al. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. Diagn Microbiol Infect Dis 1998; 30: 215-228.
51. Turner PJ. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002). Diagn Microbiol Infect Dis 2005; 51: 281-289.
52. Fomin P, Beuran M, Gradauskas A et.al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3: 35-47.
53. Breedt J, Teras J, Gardovskis J et.al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-4666.
54. Sacchidanand S, Penn RL, Embil JM et.al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-261.
55. Bouchillon SK, Hoban DJ, Johnson BM et.al. In vitro activity of tigecycline against 3,989 gram-negative and gram-positive clinical isolates from the United States: Tigecycline Evaluation and Surveillance Trial (TEST program; 2004). Diagn Microbiol Infect Dis 2005; 52: 173-179.
56. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST Technical Note on tigecycline. Clin Microbiol Infect 2006; 12: 1147-1149.